缬沙坦和螺内酯对高血压大鼠心肌胰岛素样生长因子-1 的作用

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (10): 1137-1141.

缬沙坦和螺内酯对高血压大鼠心肌胰岛素样生长因子-1 的作用

段小春, 王晋明, 王芳, 李恒, 秦晋梅

武汉大学人民医院心血管内科, 武汉430060, 湖北

收稿日期:2004-08-12 修回日期:2004-09-20 出版日期:2004-10-26 发布日期:2020-11-23
通讯作者: 王晋明, 男, 教授, 主任医师, 博士研究生导师, 研究方向:高血压的防治。Tel:027-88041911-2150 E-mail:wang jinming @163.com
作者简介:段小春, 男, 硕士研究生。
基金资助:
湖北省教育厅自然基金项目(№2000B02303; №301140080)

Effects of valsartan and spironolactone on insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats

DUAN Xiao-Chun, WANG Jin-Ming, WANG Fang, LI Heng, QIN Jin-Mei

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China

Received:2004-08-12 Revised:2004-09-20 Online:2004-10-26 Published:2020-11-23

摘要/Abstract

摘要： 目的: 观察自发性高血压大鼠(SHR) 和WKY大鼠心肌胰岛素样生长因子-1(IGF-1) 的浓度和表达及缬沙坦与螺内酯对SHRIGF-1 的影响, 探讨IGF-1 与心肌肥厚的病理机制。方法: 将18 只6 周龄SHR 随机分成3 组, 每组6 只。其中2 组分别灌胃缬沙坦30 mg·kg^-1·d^-1和螺内酯20 mg·kg^-1·d^-1, SHR 阳性对照组给正常饮水, 并与雄性同周龄WKY 大鼠比较。实验期为13 周, 放射免疫法检测心肌IGF-1 的浓度, 免疫组化法检测4 组大鼠心肌IGF-1 的表达。结果: SHR 对照组IGF-1 表达和浓度均明显高于WKY 组(P<0. 01), 缬沙坦组和螺内酯组的IGF-1 较SHR 对照组下降(P<0. 01), 而且缬沙坦组比螺内酯组下降的更明显(P<0. 05), 两组血压、LVM/BW 均显著低于SHR 组(P<0. 01) 。结论: IGF-1 在肥厚心肌中表达明显增加, 而缬沙坦和螺内酯在降压的同时可以抑制IGF-1 的表达, 提示IGF-1 在心肌肥厚发展中起一定作用。

关键词: 高血压, 心肌肥厚, 胰岛素样生长因子-1, 缬沙坦, 螺内酯

Abstract: AIM: To study the inhibitive effects of valsartan and spironolactone on expression of insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats.METHODS: 18 SHRs were randomly divided into 3 groups (n =6 in each): valsartan group treated with 30 mg·kg^-1·d^-1 valsartan, spironolactone group treated with 20 mg·kg^-1·d^-1 spironolactone, and control group treated with placebo. All were administrated by gastric perfusion. 6WKY rats were served as control. After 13 weeks administration, the expressions of IGF-1 in cardiacmycytes were measured by immunohistochemistry and the IGF-1 concentrations in myocardium were measured by radiommunoassay.RESULTS: The expression of IGF-1 was higher in SHR group than that in the WKY group (P<0. 01). Valsartan and spironolactone inhibited the expression of IGF-1. The inhibitive effects of IGF-1 in valsartan group were more significantly higher than those in spironolactone group. Valsartan and spironolactone decreased blood pressure and left ventricular mass to body weight ratio (LVM/BW).CONCLUSION: IGF-1 may play an important role in the development of cardiac hypertrophy in SHR.Valsartan and spironolactone treatment can inhibit the expression of IGF-1 and prophylaxi myocardial hypertrophy.

Key words: hypertensive, cardiac hypertrophy, insulin-like growth factor-1, valsartan, spironolactone

中图分类号:

R972.4

段小春, 王晋明, 王芳, 李恒, 秦晋梅. 缬沙坦和螺内酯对高血压大鼠心肌胰岛素样生长因子-1 的作用[J]. 中国临床药理学与治疗学, 2004, 9(10): 1137-1141.

DUAN Xiao-Chun, WANG Jin-Ming, WANG Fang, LI Heng, QIN Jin-Mei. Effects of valsartan and spironolactone on insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1137-1141.

参考文献

1 Leroith D, Werner H, Beither-Johmson D, Robers CT Jr. Molecular and cellular aspects of the insulin-like growth factor-1 receptor[J]. Endocr Rev, 1995;16(2): 143-63
2 Haddad GE, Blackwell K, Bikhazi A.Regulation of insulin-like growth factor-1 by the rennin-angiotensin system during regression of cardiar eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist[J]. Can J Physiol Pharmarol, 2003;81(2): 142-9
3 Pietro AM, Simone V, Iacopo B, Ilaria C, Gianluca P, Rita P, et al. Early sequence of cardiac adaptation and growth factor formation in pressure-and volume-overload hypertrophy[J]. Am J Phy siol Heart Circ Phy siol, 2000; 279(3): 976-85
4 Van EM, Vetter H,Grohe C. Angiotensin-converting enzyme inhibitor(ACE) inhibition atten-uates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation[J]. Br J Pharmacol, 2000;131(8): 1592-6
5 Marijke B, Jacqueline C, Russ SP, William E, Mitch PD.Angiotensin Ⅱ stimulates gene expression of cardiac insulin-like growth factor-1 and its receptor through effects on blood pressure and food intake[J]. Hypertension, 1999;34:1053-9
6 Patrick D, Marjike B, Jie D.Angiotensin Ⅱmodulation insulinlike growth factor-1 expression in the cardiovascular system[J]. Thrend Cardiovasc Med, 1996; 6(6): 187-96
7 Linda B, Katharine EC, Wolfgang J. Increased insulin-like growth factor-1 protein in human left ventricular hypertrophy [J]. ExpMol Pathol, 1999;66(1): 53-8
8 Donohue TJ, Dworkin LD, Ma J, Lango MN, Catanese VM. Antihypertensive agents that limited ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-1[J]. J Invest Med, 1997;45(9): 584-91
9 Cohen-Solal A. Role of aldosterone in heart failure[J]. Eur Heart J, 2000; 2 (Suppl.A): A17-A20
10 Claude D, Bernard S.Molecular mechanism of myocardia remodeling: the role aldosterone[J]. J Mol Cell Cardiol, 2002; 34(12): 1577-84
11 Martin VE, Hans V, Christian G.Angiotensin-converting enzyme inhibitor (ACE) inhibition attenuates insulin-like growth factor-I(IGF-I) induced cardiac fibroblast proliferation[J]. Br J Pharmacol, 2000;131(8): 1592-6
12 Pitts B. The effects of spironolactone on morbidity and mortality in patients with sever heart failure[J]. N EnglMed, 1999;341 (10): 709-17
13 Valerie R, Christophe H, Jean-Sebastien S, Abdelkarim S, Bernard S, Claude D.Angiotensin AT1 receptor subtype as a cardiac target of Aldosterone[J]. Hypertension, 1999; 33(4): 981-6

[1]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[2]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[3]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[4]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[5]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[6]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[7]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[8]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[9]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[10]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[11]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[12]	叶鹏, 谭兴, 冷岳奇, 王杨凯, 王伟忠. 基于交感神经系统的高血压非药物治疗研究现状和进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1335-1343.
[13]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[14]	崔海鞠, 马张庆, 杨魁, 汪五三, 许慧芳, 栾家杰. 褪黑素在非杓型自发性高血压大鼠体内的时辰药动学研究[J]. 中国临床药理学与治疗学, 2020, 25(12): 1337-1343.
[15]	印清, 杜荣增. 机械敏感性离子通道Piezo1在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(12): 1414-1421.